MetaCap

Pulmatrix Inc. (PULM)

NASDAQ: PULMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.27-0.15 (-10.56%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PULM stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.20
52-week range
1.06 – 4.94
Day range
1.20 – 1.42
Volume / Avg
90.74K / 35.45K
Beta
—

52-week range

$1.06$4.94

PULM stock today

Shares of Pulmatrix (PULM) finished lower on Nov 20 at $1.27, a drop of 10.56% or $0.15 per share, versus the S&P 500's 3.70% decline. Volume was 2.6x the average at 90.74K shares, a sign of unusually heavy trading. At this level, PULM sits near the bottom of its 52-week range of $1.06 to $4.94: 74.3% below the high and 19.8% above the low.

Pulmatrix has posted a net loss over the last twelve months (EPS of -$1.20), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Pulmatrix

Company profile

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Peter Ludlum CMA, MBA
Headquarters
Framingham, MA
Employees
2
IPO year
2014

Financial highlights

Full financials

Pulmatrix reported a net loss of $5.2 million, compared with a loss of $9.6 million a year earlier. Diluted earnings per share came in at -$1.41.

Pulmatrix annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—$7.81M$7.30M$6.07M$5.17M
Growth—+6.96%+20.21%+17.45%-59.09%
Net income$-5.16M$-9.56M$-14.12M$-18.84M$-20.17M
EPS (diluted)$-1.41$-2.62$-3.87$-5.46$-8.63

Earnings

Earnings history
Last reported (Sep/2026)
Nov 17, 2026
EPS actual vs est.
$-0.34 vs —

PULM news

All PULM news

Pulmatrix peers

Health Care sector
PULM peer companies
CompanyPrice% ChgMarket capCompare
BLRXBioLineRx Ltd. ADR0.9639-8.20%$4.80Mvs PULM
PCSAProcessa Pharmaceuticals Inc.1.56-7.69%$4.37Mvs PULM
CANFCan-Fite Biopharma Ltd ADR1.44-2.34%$4.35Mvs PULM
SNGXSoligenix Inc.0.2201-8.29%$5.14Mvs PULM
SCNXScienture Holdings Inc.2.28-6.45%$4.07Mvs PULM
CNSPCNS Pharmaceuticals Inc.3.56-12.75%$5.25Mvs PULM
LTRNLantern Pharma Inc.0.245-13.73%$3.89Mvs PULM
UPCUniverse Pharmaceuticals Inc. Class A1.08-20.59%$5.43Mvs PULM

Indexes, lists and sector

Pulmatrix stock FAQ

What is Pulmatrix's stock price today?

PULM last traded at $1.27 as of Nov 20, 4:00 PM EST, down 10.56% on the day. Prices are delayed at least 15 minutes.

Who is Pulmatrix's CEO?

Mr. Peter Ludlum CMA, MBA is the chief executive officer of Pulmatrix Inc., which has about 2 employees.

What is the PULM 52-week high?

The 52-week high for PULM is $4.94 and the 52-week low is $1.06. The stock is currently 74.3% below its high.

Compare PULM